|
Orlova I.Yu., Batyukina S.V., Kochetkov A.I., Piksina G.F., Plotnikova N.A., Ostroumova O.D.
State of cognitive functions in patients with various forms of atrial fibrillation
|
№1 / 2024
|
|
Shatalova N.A., Mirzaev K.B., Abdullaev Sh.P., Sozaeva Zh.A., Bochkov P.O., Asoskova A.V., Denisenko N.P., Kochetkov A.I., Ebzeeva E.Yu., Chernyaeva M.S., Shastina V.R., Ostroumova O.D., Sychev D.A.
On the possible relationship between the presence of polymorphic variants of CYP3A4/5 cytochrome genes, their metabolic activity with rivaroxaban pharmacokinetics and the development of bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease
|
№1 / 2024
|
|
A.V. Dubinina, A.I. Kochetkov, A.E. Vorobyova, S.S. Eremina, K.B. Mirzaev, O.D. Ostroumova
Analysis of the structure of comorbidities and pharmacotherapy in patients with a combination of atrial fibrillation and coronary heart disease
|
№14 / 2023
|
|
O.D. Ostroumova, A.V. Dubinina, V.A. De, A.I. Kochetkov, V.B. Dashabylova, S.S. Eremina, M.V. Klepikova
On the issue of improving the safety of antithrombotic therapy in patients with atrial fibrillation and coronary heart disease receiving antithrombotic therapy
|
№14 / 2023
|
|
G.A. Ignatenko, A.E. Bagriy, A.V. Prikolota, O.A. Prikolota, E.S. Mikhailichenko, I.A. Golodnikov, O.N. Bagriy
Experience with the use of valsartan/sacubitril in patients with chronic heart failure in combination with type 2 diabetes mellitus and paroxysmal atrial fibrillation
|
№12 / 2023
|
|
A.I. Tarzimanova
Modern treatment options for arrhythmias: focus on propafenone
|
№9/10 / 2023
|
|
I.A. Stepanenko, D.I. Sopova, V.V. Salukhov, E.L. Zaslavskaya, V.A. Tarasov, I.I. Novikov
Possibilities of screening for asymptomatic atrial fibrillation in clinical practice
|
№1-2 / 2023
|
|
A.I. Tarzimanova
Modern principles of antiarrhythmic therapy of atrial fibrillation
|
№1-2 / 2023
|
|
O.A. Polyakova, A.V. Dubinina, S.S. Telkova, Yu.A. Isaakyan, O.D. Ostroumova
Atrial fibrillation and anemia: what do we know and how to approach therapy?
|
№1-2 / 2023
|
|
A.E. Bagriy, O.A. Prikolota, A.V. Prikolota, E.S. Mikhailichenko, I.A. Golodnikov, O.N. Bagriy, K.A. Kotova
Clinical effects of dapagliflozin in patients with type 2 diabetes mellitus and paroxysmal atrial fibrillation
|
№11-12 / 2022
|
|
A.V. Tarantsova
Features of the management and follow-up of a “difficult” comorbid elderly patient with COVID-19 complications: a clinical case
|
№3 / 2022
|
|
A.I. Tarzimanova, E.E. Bykova
Antiarrhythmic therapy for atrial fibrillation in patients with the novel SARS-CoV-2 coronavirus infection: how to make the right choice?
|
№13 / 2021
|
Русский
